Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191851 | 0.88 | ADRB2 (0.67) | ADRB2ADRB1ADRB3 | |
| SCHEMBL3193098 | 0.88 | ADRB2 (0.65) | ADRB2ADRB1ADRB3 | |
| SCHEMBL3184333 | 0.88 | ADRB2 (0.66) | ADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL3183038 | 0.86 | ADRB2 (0.66) | ADRB2ADRB1ADRA1D | |
| SCHEMBL3190174 | 0.81 | ADRB2 (0.58) | ADRB2ADRB1ADRA1D | |
| SCHEMBL3175272 | 0.79 | ADRB2 (0.66) | ADRB2ADRB1ADRB3 | |
| SCHEMBL3185924 | 0.79 | ADRB2 (0.79) | ADRB2ADRB1ADRA1D | |
| SCHEMBL3838492 | 0.78 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| SCHEMBL3838496 | 0.78 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| SCHEMBL3839315 | 0.78 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662815-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2010-02-16 | — | — | US | claimed |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-05-15 | — | — | US | claimed |
| JP-2008507532-A | — | — | 2008-03-13 | — | — | JP | claimed |
| US-7317023-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | claimed |
| EP-1778638-A1 | DIARYL ETHER BETA2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006014704-A1 | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-01-26 | — | — | US | claimed |
| US-7662815-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-05-15 | — | — | US | disclosed |
| US-7317023-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1778638-A1 | DIARYL ETHER BETA2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014704-A1 | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 5/4885 |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.